Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training

Last updated: November 17, 2023
Sponsor: LMU Klinikum
Overall Status: Active - Recruiting

Phase

N/A

Condition

Tourette's Syndrome

Mood Disorders

Schizotypal Personality Disorder (Spd)

Treatment

Aerobic Endurance Training

Flexibility, strengthening and balance training

Clinical Study ID

NCT05956327
BI 576/9-1, FA 241/21-1
  • Ages 18-65
  • All Genders

Study Summary

Aerobic endurance training has shown positive effects on symptoms, cognition, daily functioning, and the structure of the hippocampus in patients with schizophrenia. The study investigates genetic and epigenetic influences on neuroplastic changes following three months of endurance training. A control group performs flexibility, strength, and balance training. The main objective is to examine the association between a genetic risk score for schizophrenia and volume increase in the CA4/DG region of the hippocampus. Additional goals include examining changes in synapses, brain structure, function, and metabolism, as well as clinical symptoms and cognitive performance.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Written informed consent for voluntary study participation.
  • Patients with schizophrenia: diagnosis of schizophrenic psychosis according to ICD10and DSM V,
  • Positive And Negative Syndrome Scale (PANSS) total score ≤ 75 before the start of theintervention
  • Reliable contraception in women of childbearing age
  • Patients must have been treated with individualized medication according to validtreatment guidelines. All antipsychotic substances are allowed, also as depotmedication. Treatment with one as well as with two antipsychotic substances ispossible. The additional administration of low- and medium-potency antipsychoticsubstances as on-demand medication for the treatment of agitation and sleep disordersis possible, provided that the daily dosage of 150 CPZ units is not exceeded. Theactive substance and dose of the individualized antipsychotic medication used toachieve the inclusion criterion of psychopathological symptom remission must beconstant for at least 2 weeks before inclusion in the study.

Exclusion

Exclusion Criteria:

  • Lack of reliability and sanity (examined by an independent psychiatrist)
  • Positive urine drug screen for illicit drugs (except benzodiazepines)
  • Acute suicide risk
  • Other relevant psychiatric axis-I disorders according to the diagnostic testingprocedure (Mini International Neuropsychiatric Interview, MINI)
  • Other relevant neurological or other disorders
  • Pregnancy or lactation

Study Design

Total Participants: 156
Treatment Group(s): 2
Primary Treatment: Aerobic Endurance Training
Phase:
Study Start date:
September 29, 2023
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • LMU Klinikum

    Munich, Bavaria 80336
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.